Articles published by Palleon Pharmaceuticals

Palleon Pharmaceuticals Announces Late-Breaking Oral Presentation on HLX79/E-602 in Autoimmune Disease at the 2026 American Society of Nephrology (ASN) Kidney Week

October 02, 2026

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of E-688/HLX316, a First-in-Class B7-H3-Targeted Sialidase for Advanced Solid Tumors

May 27, 2026

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Presents First-in-Class B7-H3 Targeted Sialidase at the 2026 AACR Annual Meeting

April 20, 2026

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals to Present on Development of HLX316/E-688 at the American Association for Cancer Research (AACR) Annual Meeting

April 02, 2026

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals to Present on Development of HLX79/E-602 in Autoimmune Disease at the American College of Rheumatology Convergence Annual Meeting and the American Society of Nephrology Kidney Week

October 22, 2025

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of E-602 (HLX79), a Potential First-In-Class Treatment for Active Glomerulonephritis

August 07, 2025

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Announces NMPA IND Clearance to Proceed with Phase 2 Clinical Trial of E-602 (HLX79), a First-In-Class Treatment for Autoimmune Diseases

April 02, 2025

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases

December 19, 2024

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 08, 2024

From Palleon Pharmaceuticals

Via Business Wire

Palleon to Present New Findings on Colorectal Tumor Microenvironment Identified with its HYDRA Platform at Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 31, 2023

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Recognized as a Fierce Biotech “Fierce 15” Company for 2023

August 28, 2023

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Announces First Patient Dosed with E-602 in Combination with Cemiplimab in GLIMMER-01 Phase 1/2 Clinical Trial

June 22, 2023

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Presents Initial Phase 1 Results from the GLIMMER-01 Clinical Trial for E-602, the First Ever Glyco-Immune Checkpoint Inhibitor

April 18, 2023

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals to Present at the Guggenheim Healthcare Talks Oncology Day

February 07, 2023

From Palleon Pharmaceuticals

Via Business Wire

Palleon Announces Issuance of a U.S. Patent for Use of Antibody Sialidase Conjugates

October 13, 2022

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals to Present at the Oppenheimer Healthcare Private Company Showcase

October 12, 2022

From Palleon Pharmaceuticals

Via Business Wire

Palleon to Present on Phase 1/2 E-602 Bi-Sialidase Trial Design at Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 11, 2022

From Palleon Pharmaceuticals

Via Business Wire

Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology

October 05, 2022

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies

June 28, 2022

From Palleon Pharmaceuticals

Via Business Wire

Palleon Presents Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase

April 08, 2022

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology

January 20, 2022

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Appoints Denis Patrick to Its Board of Directors

December 16, 2021

From Palleon Pharmaceuticals

Via Business Wire

Palleon Presents Data on Sialoglycan Degradation Platform That Enhances Anti-Tumor T-Cell Immunity

November 09, 2021

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Appoints David Johnson to Its Board of Directors

November 02, 2021

From Palleon Pharmaceuticals

Via Business Wire

Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting

October 25, 2021

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Appoints David Feltquate as Chief Medical Officer

June 09, 2021

From Palleon Pharmaceuticals

Via Business Wire

Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Patients’ Resistance to PD1 Inhibitors

April 09, 2021

From Palleon Pharmaceuticals

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.